Jump Financial, LLC Bio N Tech Se Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$88.96 - $112.35 $162,085 - $204,701	1,822 Added 71.73%	4,362 $402,000
Q4 2023 Oct 21, 2024	SELL	$90.91 - $112.75 $4.27 Million - $5.3 Million	-46,963 Reduced 94.87%	2,540 $268,000
Q4 2023 Feb 07, 2024	BUY	$90.91 - $112.75 $230,911 - $286,385	2,540 New	2,540 $268,000
Q1 2023 Oct 21, 2024	BUY	$122.57 - $153.67 $6.07 Million - $7.61 Million	49,503 New	49,503 $6.17 Million
Q1 2023 May 03, 2023	BUY	$122.57 - $153.67 $6.07 Million - $7.61 Million	49,503 New	49,503 $6.17 Million
Q1 2022 May 12, 2022	SELL	$126.25 - $231.85 $102,893 - $188,957	-815 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$216.64 - $362.52 $176,561 - $295,453	815 New	815 $210,000
Q3 2021 Nov 12, 2021	SELL	$205.93 - $447.23 $986,610 - $2.14 Million	-4,791 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$113.32 - $241.49 $682,979 - $1.46 Million	-6,027 Reduced 55.71%	4,791 $1.07 Million
Q1 2021 May 17, 2021	BUY	$85.73 - $119.5 $927,427 - $1.29 Million	10,818 New	10,818 $1.18 Million

364

38.3M

2.52M

2.18M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.